Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients
News
A combination of ilixadencel plus first-line treatment with Sutent (sunitinib) prolonged overall survival to a clinically meaningful extent in newly diagnosed patients with metastatic renal cell carcinoma (mRCC), a form of ... Read more